TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment.
Zhang P, Whipp EC, Skuli SJ, Gharghabi M, Saygin C, Sher SA, Carroll M, Pan X, Eisenmann ED, Lai TH, Harrington BK, Chan WK, Youssef Y, Chen B, Penson A, Lewis AM, Castro CR, Fox N, Cihan A, Le Luduec JB, DeWolf S, Kauffman T, Mims AS, Canfield D, Phillips H, Williams KE, Shaffer J, Lozanski A, Doong TJ, Lozanski G, Mao C, Walker CJ, Blachly JS, Daniyan AF, Alinari L, Baiocchi RA, Yang Y, Grieselhuber NR, Campbell MJ, Baker SD, Blaser BW, Abdel-Wahab O, Lapalombella R.
Zhang P, et al.
J Clin Invest. 2025 Mar 20;135(10):e184021. doi: 10.1172/JCI184021. eCollection 2025 May 15.
J Clin Invest. 2025.
PMID: 40111422
Free PMC article.